Brodt P, Blore J, Phillips N C, Munzer J S, Rioux J D
Department of Surgery, McGill University, Montreal, Quebec, Canada.
Cancer Immunol Immunother. 1989;28(1):54-8. doi: 10.1007/BF00205801.
We have investigated the ability of liposomes containing a lipophilic muramyl dipeptide, N-acetylmuramyl-L-alanyl-D-isoglutamine glycerol dipalmitate (MDP-GDP) to activate Kupffer cell tumoricidal activity in situ and to inhibit the growth of experimental hepatic micrometastases of tumor cell line H-59, a liver-homing variant of the Lewis lung carcinoma. Liposomes prepared from distearoylphosphatidylcholine/dimyristoylphosphatidylglycerol (DSPC/DMPG) and containing MDP-GDP (1 mumol and 2 micrograms, respectively) were efficiently taken up by the liver after i.v. administration. A single i.v. injection of DSPC/DMPG liposomes containing MDP-GDP was capable of inducing Kupffer cell tumoricidal activity against H-59 tumor cells as measured in vitro. Control liposomes or 100 micrograms free MDP were ineffective in inducing Kupffer cell tumoricidal activity in situ. Two treatment regimens were evaluated in vivo: firstly, C57BL/6 mice were injected with tumor cell line H-59 and subsequently treated with multiple injections of liposomal MDP-GDP. Secondly, treatment with liposomal MDP-GDP was initiated prior to tumor cell injection and continued after tumor cell injection. The ability of liposomes containing MDP-GDP to reduce the number of hepatic micrometastases using the first protocol was related to the tumor cell inoculum, significant inhibition being observed at lower liver tumor burdens (less than 25 tumor nodules). Pretreatment of the mice prior to tumor cell challenge followed by treatment afterwards greatly enhanced the efficacy of liposomal MDP-GDP and brought about a highly significant inhibition of the growth of experimental metastases even at high liver tumor burdens (greater than 50 nodules).
我们研究了含有亲脂性胞壁酰二肽(N-乙酰胞壁酰-L-丙氨酰-D-异谷氨酰胺甘油二棕榈酸酯,MDP-GDP)的脂质体原位激活库普弗细胞杀肿瘤活性以及抑制肿瘤细胞系H-59(Lewis肺癌的肝归巢变体)实验性肝微转移生长的能力。由二硬脂酰磷脂酰胆碱/二肉豆蔻酰磷脂酰甘油(DSPC/DMPG)制备并含有MDP-GDP(分别为1 μmol和2 μg)的脂质体经静脉注射后能被肝脏有效摄取。单次静脉注射含有MDP-GDP的DSPC/DMPG脂质体能够诱导库普弗细胞对H-59肿瘤细胞产生体外可测的杀肿瘤活性。对照脂质体或100 μg游离MDP在原位诱导库普弗细胞杀肿瘤活性方面无效。在体内评估了两种治疗方案:首先,给C57BL/6小鼠注射肿瘤细胞系H-59,随后多次注射脂质体MDP-GDP进行治疗。其次,在肿瘤细胞注射前开始用脂质体MDP-GDP治疗,并在肿瘤细胞注射后继续治疗。使用第一种方案时,含有MDP-GDP的脂质体减少肝微转移数量的能力与肿瘤细胞接种量有关,在较低肝脏肿瘤负荷(少于25个肿瘤结节)时观察到显著抑制。在肿瘤细胞攻击前对小鼠进行预处理,然后在之后进行治疗,极大地增强了脂质体MDP-GDP的疗效,即使在高肝脏肿瘤负荷(大于50个结节)时也能对实验性转移瘤的生长产生高度显著的抑制。